Comparison of the Sedative Effect of Inhaled Nitrous Oxide and Intranasal Midazolam in Behavior Management and Pain Perception of Pediatric Patients: A Split-mouth Randomized Controlled Clinical Trial

Navaneetha Krishnan Srinivasan¹, Pradeep Karunagaran², Veerale Panchal³, EMG Subramanian⁴

ABSTRACT

Background: Management of children has always been a challenging task in the dental office, as many children exhibit extreme fear, apprehension, and anxiety toward dental procedures. Pharmacological means of behavior management such as sedation are now at the forefront. Midazolam and nitrous oxide are the commonly employed pharmacological agents for sedation in pediatric dentistry. Though each route has its advantages and disadvantages, we compared the effect of atomized intranasal midazolam (dosage 0.3 mg/kg body weight) and nitrous oxide oxygen sedation in evaluating the behavior of child, pain experienced during local anesthesia administration, sedation level, and patient’s acceptance.

Materials and methods: A total of 35 (n = 35) anxious pediatric patients aged 4–7 years with negative and definitely negative behavioral rating were randomized to receive intranasal midazolam and inhalational nitrous oxide through mask. The overall behavior, alertness, and cry were recorded using Houpt rating scale while pain and sedation were assessed by face, legs, activity, cry, and consolability (FLACC) and Ellis sedation scores, respectively.

Results: The children who received intranasal midazolam sedation were calm, had less adverse effects, and had better acceptance of the drug. Both the techniques of sedation were found to be equally effective in terms overall behavior rating.

Conclusion: Intranasal midazolam was found to be as effective as nitrous oxide sedation for controlling behavior and providing adequate sedation in pediatric dental patients. It can also be an effective alternative for anxious patients who are unable to maintain the nitrous oxide mask throughout the dental procedure.

Keywords: Anxiety, Dental fear, Intranasal midazolam, Nitrous oxide, Overall behavior, Pediatric dentistry, Sedation

INTRODUCTION

Management of children has always been a challenging task in the dental office as many children exhibit extreme fear, apprehension, and anxiety toward dental procedures. The prevalence of dental fear and anxiety in pediatric population is around 5.7–19.5% with 9% of the children exhibiting behavior management problems.¹ Since parents are not comfortable with dentists using aversive conditioning on their children, as it leads to unnecessary emotional trauma,² pharmacological means of behavior management such as sedation and general anesthesia are now commonly used.³ Sedation is a good alternative to general anesthesia for short procedures.⁴ It involves the depression of conscious state induced by anesthetic agent, where the patient responds purposefully to verbal commands or tactile stimulation.⁵ It can be achieved through different routes of drug administration. While oral, intravenous, intramuscular, and rectal routes show promising results, their drawbacks such as low bioavailability and fear of needles limit their usage.⁶,⁷

Intranasal route of drug administration has a faster induction rate due to high vascularity and surface area of nasal mucosa⁸,⁹ and requires minimal cooperation from the child.¹⁰ Midazolam, ketamine, dexmedetomidine, and sufentanil are routinely administered through this route.¹¹,¹² Midazolam, a short-acting benzodiazepine invented in 1983,¹³ has a rapid onset of action and recovery with a wide safety margin.¹⁴,¹⁵ Considering these properties and the advantages of intranasal route, the present study used atomized administration of intranasal midazolam.

Nitrous oxide–oxygen sedation is the standard sedative technique recommended by the Council of European Dentists. Nitrous oxide exerts its analgesic and anxiolytic properties by...
causing depression in the central nervous system. It has a rapid induction and recovery. However, it is a technique sensitive procedure, as it depends on the patient’s acceptance of the mask. Continuous administration of the agent is required throughout the procedure making the treatment difficult in fearful children.

To overcome the drawbacks of nitrous oxide–oxygen sedation and to combine the advantages of intranasal midazolam, the present study compared the effect of atomized intranasal midazolam (dosage 0.3 mg/kg body weight) and nitrous oxide–oxygen sedation in evaluating the behavior of child, pain experienced during local anesthesia administration, sedation level, and patient’s acceptance.

**Materials and Methods**

**Study Design**

This study was a randomized split mouth crossover clinical trial conducted in the Department of Pediatric and Preventive Dentistry, Saveetha Institute of Medical and Technical Sciences. The study design was reviewed and approved by the Institutional Review Board of the same institution (SRB/SDMDS16PED03). The risk and benefits of the study/treatment were explained to all the parents/guardians and a written informed consent was obtained. A total of 35 (n = 35) anxious pediatric patients aged 4–7 years with negative and definitely negative behavioral rating, belonging to American Society of Anesthesiologists (ASA) physical status I, whose treatment required bilateral pulp therapy (pulpotomy/pulpectomy) in lower two quadrants under inferior alveolar nerve block, were included in the study. Children with cognitive impairment, breathing difficulties, history of systemic illness, hypersensitivity to midazolam, and children on central nervous system (CNS) depressant drugs were excluded from the study.

**Randomization**

The participants were randomized using block randomization by a blinded observer to generate a block of 35 with either 1 or 2 treatment protocol for the first appointment (where 1 = intranasal midazolam group and 2 = nitrous oxide–oxygen group). The site of treatment was also randomized. In the second appointment, the other sedation technique was used for pulp therapy on the contralateral side.

**Study Protocol**

The behavior of the patients was assessed based on the Frankl’s behavior rating scale. Only those patients on whom basic behavior management failed were included. Preoperative instructions by the American Academy of Pediatric Dentistry (AAPD) guidelines were followed.

The pain was evaluated using face, legs, activity, cry, and consolability (FLACC) score, the level of sedation by Ellis sedation score, behavior of the patient using Houpert behavior rating scale; and adverse reactions such as vomiting, sneezing, coughing, hicups, and prolonged/deep sedation caused by either of the drugs were recorded using a scale given by Shashikiran et al. At the termination of the procedure, 100% oxygen was administered for 5 minutes. The patient was discharged when the recommended discharge criteria given by AAPD were met. All the patients were followed till the next day with phone call to evaluate, if there were any posttreatment adverse reactions.

**Intranasal Midazolam Administration**

The patient was explained about the administration of the drug through euphemism. A dosage of midazolam 0.3 mg/kg (Mezolam® 5 mg/mL, Neon Laboratories Ltd.) was administered using mucosal atomizer (Wolf Tory Medical, Salt Lake City, Utah) attached to 2 mL syringe (Fig. 1 and 2). The patient’s acceptance of drug was evaluated using a scale given by al-Rakaf et al. in 2001. Inferior alveolar nerve block was then administered (2% lignocaine with 1:200,000 adrenaline) after signs of sedation such as being relaxed with slurring or slowing of speech was visible on the patient.

**Nitrous Oxide–Oxygen Administration**

Each child was demonstrated the placement of nasal mask using tell show do and euphemisms. The flow rate was determined by initial administration of 100% oxygen for 2–3 minutes. Then, a preadjusted mixture of nitrous oxide–oxygen was administered in the concentration of 30–70% using Matrx Porter Digital Relative analgesia machine (Fig. 3 and 4). The patient’s acceptance of nasal mask was evaluated using a scale given by Wood in 2010. Local anesthesia administration was initiated after the first signs of sedation.
Comparison between Intranasal Midazolam and Inhalational Nitrous Oxide in Pediatric Dentistry

Results
A total of 35 participants were included in the study with a mean age of 5.66 ± 0.77 years.

There was no significant difference between the two sedation regimens with regard to overall behavior or crying—57.1% of the children showed excellent behavior under nitrous oxide sedation while 51.4% in midazolam group had excellent behavior.

Alertness during Treatment
Total cooperation with no limb movement, while 57% of the participants sedated using nitrous oxide had a score of 1. 20% of children who received midazolam sedation had a score of 3 (more uninvited limb movement; small degree of restlessness and anxiety; patient less cooperative; still able to perform all dental procedures).

94% of children who received midazolam sedation were relaxed and comfortable during the treatment. While 4% showed a mild discomfort during local anesthesia administration. The mean FLACC score was 1.57 ± 2.60 for nitrous oxide and 2.77 ± 3.70 for midazolam group, respectively. The FLACC score was significantly lower in nitrous oxide group as compared to midazolam group ($p = 0.049$).

In Table 1, the physiological parameter observation has been described and there was no significant difference in the physiologic parameters for both the groups except for the heart rate at T2 interval. It was 106.64 ± 12.68 bpm on nitrous oxide administration and 103.29 ± 12.69 bpm under midazolam at T2. The difference between the heart rates at T2 interval was statistically significant ($p = 0.049$) compared to T1 and T3.

Adverse Effects
There was a low incidence of vomiting (2.2%) with nitrous oxide sedation and none with midazolam ($p = 0.020$). Four participants had sneezing/coughing/hiccups during midazolam sedation and none with nitrous oxide ($p = 0.039$). No other adverse effect was reported with either of the sedation regimens.

Discussion
Behavior management is an important aspect of pediatric dentistry to deliver optimal treatment for anxious children. Pharmacological behavior management strategies are always considered as an alternative when nonpharmacological behavior management strategies fail to reduce anxiety. According to AAPD, sedation is aimed at providing safe and effective dental treatment. Thus, in the present study, we compared the behavioral pattern of children with two methods of delivering sedation—intranasal midazolam and inhaled nitrous oxide—oxygen sedation.

This study followed a split mouth design, which allowed the patient to experience both the methods of sedation. It also permits less variation in the outcome after sedation. All the outcomes were assessed using objective methods of evaluation by a trained observer who was blinded to eliminate the risk of bias.

Fuks et al. had stated that 0.2 mg/kg midazolam was similar in its effectiveness as 0.3 mg/kg of the drug. However, they had used midazolam in combination with 50% nitrous oxide. Since the present study has not used midazolam in combination with other agents, higher dosage of 0.3 mg/kg of midazolam was used.

Statistical Analysis
Analysis was done using SPSS software version 23 (IBM SPSS Statistics for Windows, Version 23.0, Armonk, NY: IBM Corp. Released 2015). As the study is “split mouth design,” to compare mean values between groups, paired t-test was applied. To compare proportions between groups, McNemar’s Chi-square test was applied. $p < 0.05$ was considered to be statistically significant.
promotes rapid absorption of the drug into systemic circulation. A concentration of 30% was used since studies have demonstrated that 20–30% concentration provides adequate sedation without the risk of oversedation. A premixed dose was given to standardize the dose of nitrous oxide for all the patients undergoing sedation.

Bahetwar et al. had used 0.3 mg/kg of midazolam when not used in combination with other agents. Midazolam was administered through intranasal route through mucosal atomization. It produces a fine 30 μm particle spray providing 55% bioavailability of the drug. The semipermeable soft plug in the mucosal atomizer cushions the naris and prevents any back-leak of the drug.

### Table 1: Comparison of physiologic parameters between nitrous oxide sedation and intranasal midazolam sedation

| Variables                | Group          | N  | Mean  | Std deviation | t-value | p-value |
|--------------------------|----------------|----|-------|---------------|---------|---------|
| Oxygen saturation-T1     | Nitrous oxide  | 35 | 99.71 | 1.126         | 0.269   | 0.790   |
|                          | Midazolam      | 35 | 99.66 | 0.906         |         |         |
| Oxygen saturation-T2     | Nitrous oxide  | 35 | 99.60 | 1.193         | 1.320   | 0.196   |
|                          | Midazolam      | 35 | 99.23 | 1.285         |         |         |
| Oxygen saturation-T3     | Nitrous oxide  | 35 | 99.63 | 1.003         | 0.734   | 0.468   |
|                          | Midazolam      | 35 | 99.46 | 1.039         |         |         |
| Heart rate- T1           | Nitrous oxide  | 35 | 102.77| 11.951        | 0.084   | 0.934   |
|                          | Midazolam      | 35 | 102.66| 13.346        |         |         |
| Heart rate- T2           | Nitrous oxide  | 35 | 106.54| 12.682        | 2.031   | 0.049   |
|                          | Midazolam      | 35 | 103.29| 12.629        |         |         |
| Heart rate- T3           | Nitrous oxide  | 35 | 103.69| 11.749        | 0.049   | 0.961   |
|                          | Midazolam      | 35 | 103.77| 11.270        |         |         |
| Respiratory rate-T1      | Nitrous oxide  | 35 | 22.57 | 2.266         | 0.085   | 0.932   |
|                          | Midazolam      | 35 | 22.60 | 2.637         |         |         |
| Respiratory rate-T2      | Nitrous oxide  | 35 | 23.00 | 2.722         | 0.000   | 1.0     |
|                          | Midazolam      | 35 | 23.00 | 3.115         |         |         |
| Respiratory rate-T3      | Nitrous oxide  | 35 | 23.03 | 2.256         | 0.821   | 0.417   |
|                          | Midazolam      | 35 | 22.80 | 2.098         |         |         |
Dental treatment was successfully completed in both the methods of sedation with limited movements, crying, and good overall behavior. We found no difference in the behavior of the child with intranasal midazolam and nitrous oxide–oxygen sedation. Intranasal midazolam was found to be as effective as nitrous oxide–oxygen sedation in controlling the behavior of the child during dental treatment. In previous studies, orally administered midazolam was used and was found to have a similar efficacy as nitrous oxide sedation.31

42% of the children in our study readily accepted the nasal mask without resistance since a proper tell show do technique was used prior to the mask placement. But, displeasure was associated with 91.4% of the children during the intranasal administration of the drug, which was due to the bitter taste of the drug. FLACC scores were found to be similar in both groups of sedation. However, Wilson et al. showed less children recalling local anesthesia administered with nitrous oxide sedation than oral midazolam sedation suggesting lower pain level with N₂O as compared to oral midazolam.32

Studies show that coughing and sneezing are the most common adverse effects of intranasal midazolam. This was due to the increased volume of the drug trickling through oropharynx.33,34 Hence, in the present study, we used a higher concentration of intranasal midazolam (5 mg/mL) by mucosal atomization in order to prevent the adverse effects. The present study reported an incidence of sneezing in 11.4% of the patients for intranasal midazolam. The findings of our study were in resonance with the findings of Bahetwar et al.11 who also reported minimal adverse effects with the use of highly concentrated intranasal midazolam.

Vomiting was reported in 2.2% of the patients receiving nitrous oxide sedation. However, it did not have effect on the overall treatment outcome and completion of the procedure. We believe that the low incidence of vomiting was due to strict preoperative fasting. Zier and Liu35 also reported 2.2% incidence of vomiting which is in concurrence with the incidence reported in present study. The findings of our study re-emphasize the practice of alerting parents to the complications during the informed consent process to relieve anxiety and prepare them for postoperative care of the child.36 We believe that the emesis might have been caused by the action of nitrous oxide on central opioid and dopaminergic receptors,37 diffusion of nitrous oxide into the middle ear cavity,36 and bowel distension. The adverse effects and acceptance could relate to the maturity level of the children and can influence their ability to cope with the feelings of sedation. This was observed by Wilson et al. in 2006 when they used a higher dose of midazolam in 10–16-years old and found this age could have influenced their behavior during sedation.

There was a statistically significant difference (103.29 ± 12.629 in midazolam versus 106.54 ± 12.682 in nitrous oxide) in the heart rates during local anesthesia administration for both the methods of sedation at the T2 interval (p = 0.049). However, we feel that the difference was not clinically significant.

The limitation of the present study is that the onset of sedation, recovery time, and the effect of other physiologic parameters were not evaluated. These factors would further provide better comparison for two different methods of sedation. The present study has only evaluated two most commonly used agents for sedation in anxious children. Comparison of multiple drug regimen used for sedation will aid in determining better method of sedation in pediatric dental patients.

**Conclusion**

Both nitrous oxide and intranasal midazolam were effective in controlling the anxiety with optimum level of sedation to complete the dental treatment. Intranasal midazolam was found to be as effective as nitrous oxide sedation for controlling behavior and providing adequate sedation in pediatric dental patients. It can also be an effective alternative for anxious patients who are unable to maintain the nitrous oxide mask throughout the dental procedure.

**Clinical Significance**

Intranasal midazolam is as effective as nitrous oxide sedation for controlling behavior and providing adequate sedation in pediatric dental patients. It can also be an effective alternative for anxious patients who are unable to maintain the nitrous oxide mask throughout the dental procedure.

**References**

1. Klingberg G, Broberg AG. Dental fear/anxiety and dental behaviour management problems in children and adolescents: a review of prevalence and concomitant psychological factors. Int J Paediatr Dent 2007;17(6):391–406. DOI: 10.1111/j.1365-2663.2007.00872.x
2. Wilson S, Pharmacologic behaviour management for pediatric dental treatment. Pediatr Clin North Am 2000;47(5):1159–1175. DOI: 10.1016/s0031-3955(05)70262-5
3. Lawrence SM, McTigue D, Wilson S, et al. Parental attitudes toward behaviour management techniques used in pediatric dentistry. Pediatr Dent 1991;13(3):151–155.
4. Fields H, Machen JB, Murphy MG. Acceptability of various behaviour management techniques relative to types of dental treatment. Pediatr Dent 1984;6(4):199–203.
5. Coté CJ, Wilson S, American Academy of Pediatrics. American Academy of Pediatric Dentistry. Guidelines for monitoring and management of pediatric patients before during and after sedation for diagnostic and therapeutic procedures: update. Pediatrics 2016;138:e20161212. DOI: 10.1542/peds.2016-1212
6. Malamed SF. Sedation: A Guide to Patient Management. St. Louis Missouri: Mosby; 1995.
7. Roelofs JA, van der Bijl P, Comparison of rectal midazolam and diazepam for premedication in pediatric dental patients. J Oral Maxillofacial Surg 1993;51(5):525–529. DOI: 10.1016/s0278-2391(10)80507-5
8. Hussain AA. Mechanism of nasal absorption of drugs. Prog Clin Biol Res 1989;292:261–272.
9. Lee-Kim SJ, Fadavi S, Punwani I, et al. Nasal versus oral midazolam sedation for pediatric dental patients. J Dent Child (Chic) 2004;71:126–130.
10. Al-Rakaf H, Bello L, Turkustani A, et al. Intra-nasal midazolam in conscious sedation of young paediatric dental patients. Int J Paediatr Dent 2001;11:33–40. DOI: 10.1046/j.1365-263x.2001.00237.x
11. Bahetwar SK, Pandey RK, Saksena AK, et al. A comparative evaluation of intranasal midazolam, ketamine and their combination for sedation of young uncooperative pediatric dental patients: a triple blind randomized crossover trial. J Clin Pediatr Dent 2011;35(4):415–420. DOI: 10.17796/jcpd.35.4.143h333y4705u2574
12. Braham RL, Bogetz MS, Kimura M. Pharmacologic patient management in pediatric dentistry: an update. ASDC J Dent Child 2003;60(4-5):270–280.
13. Wilson KE, Girdler NM, Welbury RR. Randomized, controlled, cross-over clinical trial comparing intravenous midazolam sedation with nitrous oxide sedation in children undergoing dental extractions. Br J Anaesth 2003;91(6):850–856. DOI: 10.1093/bja/aeg278
Comparison between Intranasal Midazolam and Inhalational Nitrous Oxide in Pediatric Dentistry

14. Torres-Pérez J, Tapia-García I, Rosales-Berber MA, et al. Comparison of three conscious sedation regimens for pediatric dental patients. J Clin Pediatr Dent 2007;31:183–186. DOI: 10.17796/jcpd.31.3.e82526dq0432375n0
15. Papineni A, Lourenço-Matharu L, Ashley PF. Safety of oral midazolam sedation use in paediatric dentistry: a review. Int J Paediatr Dent 2014;24(1):2–13. DOI: 10.1111/ipd.12017
16. American Academy of Pediatric Dentistry. Guideline on use of nitrous oxide for pediatric dental patients. Pediatr Dent 2013;35(5):E174–E178.
17. Clark MS, Brunick A. Handbook of Nitrous Oxide and Oxygen Sedation. St. Louis: Elsevier Health Sciences; 2014.
18. Hosey MT, Blinkhorn AS. An evaluation of four methods of assessing the behaviour of anxious child dental patients. Int J Paediatr Dent 1995;5(2):87–95. DOI: 10.1111/j.1365-263x.1995.tb00170.x
19. American Academy of Pediatrics, Coté CJ, Wilson S, et al. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics, 2006;118(6):2587–2602. DOI: 10.1542/peds.2006-2780
20. Merkel S, Vogeel-Lewis T, Malviya S. Pain assessment in infants and young children: the FLACC scale. Am J Nurs 2002;102(10):55–58. DOI: 10.1097/00000446-200210000-00024
21. Ellis S. Response to intravenous midazolam sedation in general dental practice. Br Dent J 1996;180:417–420. DOI: 10.1036/sj.bdj.4809108
22. Houpt MI, Weiss NJ, Koenigsberg SR, et al. Comparison of chloral hydrate with and without promethazine in the sedation of young children. Pediatr Dent 1985;7(1):41–46.
23. Shashikiran ND, Reddy SVV, Yavagal CM. Conscious sedation—an artist’s science! An Indian experience with midazolam. J Indian Soc Pedod Prev Dent 2006;24(1):7–14. DOI: 10.4103/0970-4388.22830
24. Wood M. The safety and efficacy of intranasal midazolam sedation combined with inhalation sedation with nitrous oxide and oxygen in paediatric dental patients as an alternative to general anaesthesia. SAAD Dig 2010;26:12–22.
25. Policy on the use of deep sedation and general anesthesia in the pediatric dental office. Pediatr Dent 2016b;38(6):94–95.
26. American Academy of Pediatric Dentistry. Guideline for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Reference manual. Pediatr Dent 2015;36:209–225.
27. Fuks AB, Kaufman E, Ram D, et al. Assessment of two doses of intranasal midazolam for sedation of young pediatric dental patients. Pediatr Dent 1994;16(4):301–305.
28. Knoester PD, Jonker DM, Van Der Hoeven RT, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray: A study in healthy volunteers. Br J Clin Pharmacol 2002;53(5):501–507. DOI: 10.1046/j.1365-2125.2002.01588.x
29. Veerkamp JS, Gruythuysen RJ, Hoogstraten J, et al. Anxiety reduction with nitrous oxide: a permanent solution? ASDC J Dent Child 1995;62:44–48.
30. Primus RE, Guelmann M. Comparison of drops versus spray administration of intranasal midazolam in two- and three-year-old children for dental sedation. Pediatr Dent 2005,27(5):401-408.
31. Wilson S. Pharmacological management of the pediatric dental patient. Pediatr Dent 2004;26(2):131–136.
32. Wilson KE, Girdler NM, Welbury RR. A comparison of oral midazolam and nitrous oxide sedation for dental extractions in children. Anesthesia 2006;61(12):1138–1144. DOI: 10.1111/j.1365-2044.2006.04835.x
33. Gilchrist F, Cairns AM, Leitch JA. The use of intranasal midazolam in the treatment of paediatric dental patients. Anesthesia 2007;62(12):1262–1265. DOI: 10.1111/j.1365-2044.2007.05260.x
34. Lloyd CJ, Alredy T, Lowry JC. Intranasal midazolam as an alternative to general anesthesia in the management of children with oral and maxillofacial trauma. Br J Oral Maxillofac Surg 2000;38(6):593–595. DOI: 10.1054/bjom.2000.0534
35. Zier JL, Liu M. Safety of high-concentration nitrous oxide by nasal mask for pediatric procedural sedation: experience with 7802 cases. Pediatr Emerg Care 2011;27(12):1107–1112. DOI: 10.1097/PEC.0b013e31823affed6
36. Gentz R, Casamassimo P, Amini H, et al. Safety and efficacy of 3 pediatric midazolam moderate sedation regimens. Anesth Prog 2017;64(2):66–72. DOI: 10.2344/anpr-64-02-04
37. Davis I, Moore JR, Lahiri SK. Nitrous oxide and the middle ear. Anesthesia 1979;34:147–151. DOI: 10.1111/j.1365-2044.1979.tb06269.x
38. Orhan-Sungur M, Apfel C, Akça O. Effects of nitrous oxide on intraoperative bowel distension. Curr Opin Anaesthesiol 2005;18:620–624. DOI: 10.1097/01anco.00000188417.00011.7b